Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma

Mei Ju Chen, Yen Cheng Chen, Ching Kuang Chou, Wen-Ming Hsu

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and bimatoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Eighty-two (82) consecutive CACG patients with an IOP greater than 19 mmHg after a peripheral iridotomy were recruited. CACG was defined as chronic elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to two groups based on daily treatment with either latanoprost 0.005% or bimatoprost 0.03% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM on the same day at baseline and also at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and bimatoprost groups was significantly reduced when compared to the baseline value (21.6 ± 1.9 to 16.4 ± 2.5 mmHg and 22.1 ± 2.0 to 16.9 ± 2.4 mmHg, respectively; P < 0.001 for both). There was no significant difference in IOP reduction between the two treatment groups (P = 0.40). At 4 and 8 weeks, the IOP changes from baseline were statistically significant at both times for both drugs (all P < 0.001). Conclusions: Both latanoprost and bimatoprost significantly reduced IOP in CACG patients who were inadequately treated by laser peripheral iridotomy.

Original languageEnglish
Pages (from-to)559-565
Number of pages7
JournalJournal of Ocular Pharmacology and Therapeutics
Volume23
Issue number6
DOIs
Publication statusPublished - Dec 1 2007
Externally publishedYes

Fingerprint

latanoprost
Angle Closure Glaucoma
Intraocular Pressure
Gonioscopy
Bimatoprost
Optic Nerve Diseases

ASJC Scopus subject areas

  • Ophthalmology
  • Pharmacology
  • Pharmacology (medical)

Cite this

Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma. / Chen, Mei Ju; Chen, Yen Cheng; Chou, Ching Kuang; Hsu, Wen-Ming.

In: Journal of Ocular Pharmacology and Therapeutics, Vol. 23, No. 6, 01.12.2007, p. 559-565.

Research output: Contribution to journalArticle

@article{7d3cdb5b99da49aeb76912670b7874cb,
title = "Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma",
abstract = "Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and bimatoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Eighty-two (82) consecutive CACG patients with an IOP greater than 19 mmHg after a peripheral iridotomy were recruited. CACG was defined as chronic elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to two groups based on daily treatment with either latanoprost 0.005{\%} or bimatoprost 0.03{\%} in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM on the same day at baseline and also at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and bimatoprost groups was significantly reduced when compared to the baseline value (21.6 ± 1.9 to 16.4 ± 2.5 mmHg and 22.1 ± 2.0 to 16.9 ± 2.4 mmHg, respectively; P < 0.001 for both). There was no significant difference in IOP reduction between the two treatment groups (P = 0.40). At 4 and 8 weeks, the IOP changes from baseline were statistically significant at both times for both drugs (all P < 0.001). Conclusions: Both latanoprost and bimatoprost significantly reduced IOP in CACG patients who were inadequately treated by laser peripheral iridotomy.",
author = "Chen, {Mei Ju} and Chen, {Yen Cheng} and Chou, {Ching Kuang} and Wen-Ming Hsu",
year = "2007",
month = "12",
day = "1",
doi = "10.1089/jop.2007.0037",
language = "English",
volume = "23",
pages = "559--565",
journal = "Journal of Ocular Pharmacology and Therapeutics",
issn = "1080-7683",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Comparison of the effects of latanoprost and bimatoprost on intraocular pressure in chronic angle-closure glaucoma

AU - Chen, Mei Ju

AU - Chen, Yen Cheng

AU - Chou, Ching Kuang

AU - Hsu, Wen-Ming

PY - 2007/12/1

Y1 - 2007/12/1

N2 - Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and bimatoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Eighty-two (82) consecutive CACG patients with an IOP greater than 19 mmHg after a peripheral iridotomy were recruited. CACG was defined as chronic elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to two groups based on daily treatment with either latanoprost 0.005% or bimatoprost 0.03% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM on the same day at baseline and also at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and bimatoprost groups was significantly reduced when compared to the baseline value (21.6 ± 1.9 to 16.4 ± 2.5 mmHg and 22.1 ± 2.0 to 16.9 ± 2.4 mmHg, respectively; P < 0.001 for both). There was no significant difference in IOP reduction between the two treatment groups (P = 0.40). At 4 and 8 weeks, the IOP changes from baseline were statistically significant at both times for both drugs (all P < 0.001). Conclusions: Both latanoprost and bimatoprost significantly reduced IOP in CACG patients who were inadequately treated by laser peripheral iridotomy.

AB - Purpose: The aim of this study was to compare the intraocular pressure (IOP)-lowering effect of latanoprost and bimatoprost as primary therapy in patients with chronic angle-closure glaucoma (CACG) after peripheral iridotomy. Methods: Eighty-two (82) consecutive CACG patients with an IOP greater than 19 mmHg after a peripheral iridotomy were recruited. CACG was defined as chronic elevated IOP, glaucomatous optic neuropathy, and a corresponding visual field defect in eyes with occludable angle and peripheral anterior synechiae on gonioscopy. Patients were randomly assigned to two groups based on daily treatment with either latanoprost 0.005% or bimatoprost 0.03% in the evening for 12 weeks. The IOP was measured at 9 AM and 4 PM on the same day at baseline and also at 4, 8, and 12 weeks. Between-group differences in mean diurnal IOP and IOP reduction were analyzed. Results: After 12 weeks of treatment, mean IOP for both the latanoprost and bimatoprost groups was significantly reduced when compared to the baseline value (21.6 ± 1.9 to 16.4 ± 2.5 mmHg and 22.1 ± 2.0 to 16.9 ± 2.4 mmHg, respectively; P < 0.001 for both). There was no significant difference in IOP reduction between the two treatment groups (P = 0.40). At 4 and 8 weeks, the IOP changes from baseline were statistically significant at both times for both drugs (all P < 0.001). Conclusions: Both latanoprost and bimatoprost significantly reduced IOP in CACG patients who were inadequately treated by laser peripheral iridotomy.

UR - http://www.scopus.com/inward/record.url?scp=36749008081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=36749008081&partnerID=8YFLogxK

U2 - 10.1089/jop.2007.0037

DO - 10.1089/jop.2007.0037

M3 - Article

C2 - 18001247

AN - SCOPUS:36749008081

VL - 23

SP - 559

EP - 565

JO - Journal of Ocular Pharmacology and Therapeutics

JF - Journal of Ocular Pharmacology and Therapeutics

SN - 1080-7683

IS - 6

ER -